NCT05088369View on ClinicalTrials.gov

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

HM201

HM201 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

DRUG

HM201

HM201 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

Trial Locations (1)

4006

Nucleus Network Pty Ltd, Herston

Sponsors

Lead Sponsor

Syneos Health
All Listed Sponsors
collaborator

Himuka AM Pharma Corp.

UNKNOWN

lead

Syneos Health

OTHER